Arthneeti
Influx Healthtech Ltd Q2 FY27 results are out (Jul–Sep 2026) →See revenue, profit and what management said. You are viewing Q1 FY26.
IH

Influx Healthtech Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Influx Healthtech Q1 FY26: Revenue ₹104.9 Cr, PAT ₹13.4 Cr

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Influx Healthtech Ltd Q1 FY26 key numbers

Revenue
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26).

As stated in Influx Healthtech Ltd's Q1 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Influx Healthtech Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹280
Market cap₹634 Cr
P/E30.9

The short version

FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). EBITDA for FY25: ₹20.6 crores, a 22% YoY increase (Page 4) - EBITDA Margin FY25: 19.6%, up 269 bps from FY24 (Page 28) - Profit after Tax (PAT) for FY25: ₹13.4 crores, a 20% YoY increase (Pages 4, 28) - PAT Margin FY25: 12.8%, up 165 bps from FY24 (Page 28) - Operating margin (EBITDA margin) explicitly reported as 19.6% for FY25 (Pages 4, 28)

From Influx Healthtech Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26).
  • Revenue split FY25: Nutraceuticals (₹94.0 cr, 90%), Cosmetics (₹6.4 cr, 6%), Ayurvedic (₹3.2 cr, 3%), Others (₹1.2 cr, 1%) (Page 5).
  • Product portfolio expanded by 6% to 3,559 products in FY25 (Page 4).
  • Highest annual revenue recorded in FY25, indicating growth momentum (Page 4).

2 more points from Influx Healthtech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Influx Healthtech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Planned capacity expansion to increase overall capacity by 2.5x post utilization of IPO proceeds (Page 16). - ₹23 crores investment to establish a new manufacturing facility under the nutraceutical division on a 3,204 mt2 site (Page 16). - ₹12 crores planned for setting up a manufacturing facility under the veterinary food division on a 1,350 mt2 site (Page 16). - ₹3 crores capital expenditure planned for procuring machinery to enhance manufacturing capacity in homecare and cosmetic divisions (Page 16). - Capacity utilization prior to IPO proceeds: • Nutraceuticals: 93% • Cosmetics & Ayurvedic: 90% • Pet supplements & Homecare: 66% (Page 16). - Expanded tablet capacity to 1,230 kg/day; doubled liquid & sachet throughput to 48,000 bottles & 98,000 sachets per shift (Page 17).

2 more points from Influx Healthtech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Influx Healthtech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Influx Healthtech Ltd said on order book & pipeline — free account, 30 seconds.

Continue your research

What Influx Healthtech's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Influx Healthtech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Influx Healthtech Ltd Q1 FY26 results?

FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). EBITDA for FY25: ₹20.6 crores, a 22% YoY increase (Page 4) - EBITDA Margin FY25: 19.6%, up 269 bps from FY24 (Page 28) - Profit after Tax (PAT) for FY25: ₹13.4 crores, a 20% YoY increase (Pages 4, 28) - PAT Margin FY25: 12.8%, up 165 bps from FY24 (Page 28) - Operating margin (EBITDA margin) explicitly reported as 19.6% for FY25 (Pages 4, 28)

What is Influx Healthtech Ltd share price analysis?

Influx Healthtech Ltd currently shows a neutral. The stock trades at a P/E of 30.9 with a market cap of ₹634 Cr. Investors should review the full earnings analysis for detailed insights.

Is Influx Healthtech Ltd planning capital expenditure?

Planned capacity expansion to increase overall capacity by 2.5x post utilization of IPO proceeds (Page 16).

Keep Influx Healthtech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.